Abstract
Hypertensive disorders of pregnancy (HDP) represent a frequent disorder among pregnancies. Women with severe hypertension in pregnancy are at increased risk of maternal complications and require antihypertensive drug therapy. This study aimed to systematically review randomized control trials of antihypertensive drug(s) treating non-severe hypertension during pregnancy to estimate the effectiveness and safety of this intervention. On May 8, 2018, we searched PubMed, Cochrane Library, and Ichu-Shi with no restriction on publication year. We selected randomized control trials that involved women with HDP being treated with antihypertensive drug(s) as intervention. Fourteen trials (1804 women) were identified for meta-analysis. There were no significant differences in the risk of maternal death (373 women; risk ratio (RR) 0.70; 95% confidence interval (CI) 0.04 to 11.45), proteinuria (1214 women; RR 1.00; 95% CI 0.67 to 1.49), side effects (360 women; RR 2.69; 95% CI 0.32 to 22.64), cesarean section (1239 women; RR 0.97; 95% CI 0.82 to 1.15), neonatal and birth death (1548 women; RR 0.80; 95% CI 0.43 to 1.49), preterm birth (904 women; RR 0.86; 95% CI 0.53 to 1.39), or small for gestational age infants (1082 women; RR 1.04; 95% CI 0.66 to 1.63) with antihypertensive drug therapy versus placebo or no treatment. The current review suggests that antihypertensive drug therapy does not reduce or increase the risk of maternal or perinatal outcomes. Further studies are needed to build reliable estimates of the effectiveness and safety of antihypertensive drug therapy for women with HDP.
Similar content being viewed by others
Introduction
Hypertensive disorders of pregnancy (HDP) is a frequent disorder, with a reported incidence of 10% to 15% among pregnancies [1]. HDP is a leading cause of maternal/fetal morbidity and mortality, the most common being preeclampsia-eclampsia [2]. The definition of HDP includes preeclampsia-eclampsia, chronic hypertension, chronic hypertension with superimposed preeclampsia, and gestational hypertension [3]. Gestational hypertension is defined as sustained systolic blood pressure (BP) of 140 mmHg or higher and/or diastolic BP of 90 mmHg or higher with onset after 20 weeks of gestation in the absence of proteinuria. Chronic hypertension is defined as preexisting hypertension or hypertension diagnosed before 20 weeks of gestation.
Sustained severe hypertension in pregnancy is considered to be a risk factor for maternal and perinatal complications. On the other hand, excessive BP lowering may cause dizziness or fetal distress. There is consensus that severe hypertension (defined as a sustained systolic BP of 160 mmHg or higher and/or diastolic BP of 110 mmHg or higher) during pregnancy should be treated to decrease the maternal and perinatal risk of complications [3]. However, the role of antihypertensive drug therapy for non-severe hypertension during pregnancy (defined as a systolic BP of 140 to 159 mmHg and/or diastolic BP of 90 to 109 mmHg) remains unclear. Thus, this study aimed to systematically review and meta-analyze available data from randomized controlled trials on the effect of antihypertensive drug therapy for non-severe hypertension during pregnancy.
Methods
The methods for this systematic review were developed according to recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement [4]. No ethical approval was required.
Literature search
We searched Medline (PUBMED), the Cochrane Central Register of Controlled Trials (CENTRAL), and Ichu-Shi (Japanese). We limited the search from their earliest entries until May 8, 2018. Searches of exploded MeSH terms “Hypertension, Pregnancy-Induced” and the text words “Hypertensi or High Blood Pressure” and “therap or treatment or pharmacotherapy or antihypertensi” and “Randomized Controlled Trial” (Medline) and “Antihypertensive Agents” (CENTRAL) were performed individually. There were language restrictions for Japanese and English (Medline). Reference lists from identified trials and review articles were manually scanned to identify any other relevant studies (Supplementary Appendix).
Study selection criteria
Two reviewers (S.O and J.S) independently and in duplicate screened the titles and abstracts of all identified studies using a priori selection criteria. Subsequently, reviewers independently assessed eligibility of the full texts of potentially eligible studies. Reviewers resolved discrepancies through discussion. We included randomized controlled trials that compared non-severe hypertension during pregnancy (defined as a systolic BP of 140 to 169 mmHg and/or diastolic BP of 90 to 109 mmHg). Comparisons were of one or more antihypertensive drug(s) with placebo, with no antihypertensive drug. Women were included regardless of whether they had proteinuria or not, and irrespective of previous antihypertensive treatment or whether the pregnancy was singleton or multiple.
Data extraction
The titles, abstracts and selected full texts generated from the literature search were independently screened by 2 of the authors (S.O. and J.S.). The authors were not masked to the results of the study or the authors. Where 2 articles published results from the same study, individual pertinent outcomes were extracted from both articles. The following outcome measures were recorded for each study: maternal death, proteinuria (1+ or more or 300 mg/L or 5 g/24 h), side effects (rash, headache, vertigo, generalized weakness, lethargy, diarrhea), cesarean section, neonatal and birth death, preterm birth (defined as less than 36 or 37 completed week’s gestation), and small for gestational age infants. The PRISMA statement was considered and observed for all procedures and reporting.
Study quality assessment
Two reviewers (S.O. and J.S.) independently assessed the risk of bias of each trial using the Risk of Bias tool, which was developed by Cochrane [5]. The risk bias in each of following domains was assessed: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other factors.
Statistical method
We carried out statistical analyses using Review Manager Version 5.2 (RevMan 5.2) software (Nordic Cochrane Centre, Copenhagen, Denmark). All outcomes were analyzed on an intention-to-treat bias. Meta-analysis was performed using a fix-effects model when there was more than 1 study with analyzable data. The initial analysis of treatment effects was performed by antihypertensive agent (treat) versus placebo or no treatment (control). Treatment effects are presented as estimated differences in mean or risk ratio with 95% confidence interval (CI). Forest plots ware constructed to graphically represent the results. Heterogeneity was measured using the inconsistency (I2) statics, which estimates the percentage of total variation across trials that can be attributed to heterogeneity rather than chance. I2 values of less than 25% and more than 75% represent low and high inconsistency, respectively [6]. P values of less than 0.05 were considered statistically significant. No other units of analysis were used in this review.
Results
Description of the included studies
From three databases, 617 potential studies were identified. We identified 6 additional candidate studies by reviewing bibliographies of included articles. After removal of duplicates, the initial search generated 194 titles and abstracts for review. From reading abstracts, 171 articles were excluded on the basis of study design, and 23 full-text articles were retrieved. Of those, 14 articles met the final inclusion criteria and formed the basis of this systematic review. The study selection process is shown in Fig. 1. The characteristics of the included studies are described in Table 1.
Fourteen trials (1804 women) were included in this review. Of these, 7 (790 women) were conducted in European countries [7,8,9,10,11,12,13], 4 (640 women) in the USA [14,15,16,17], and 3 (374 women) in other countries [18,19,20]. One trial was published in the 1970s [12], 4 in the 1980s [10, 11, 14, 17], 7 in the 1990s [7,8,9, 13, 15, 16, 20], and 2 after the year 2000 [18, 19]. The antihypertensive drugs used in these trials included: alpha agonists (methyldopa), beta blockers (atenolol, labetalol, oxprenolol), and a calcium channel blocker (isradipine). Six trials were placebo-controlled studies of a single antihypertensive drug (537 women) [7, 8, 10, 11, 13, 14], and 8 were studies of a single antihypertensive drug or 2 antihypertensive drugs compared to no drug treatment (1267 women) [9, 12, 15,16,17,18,19,20].
Effect of intervention: antihypertensive drugs versus none
Overall, 14 trials with a total of 1804 women compared an antihypertensive drug with placebo or no antihypertensive drug.
Maternal outcomes
Only 3 small trials reported maternal death (373 women; risk ratio (RR) 0.70; 95% CI 0.04 to 11.45) (Fig. 2a). There is no overall difference in the risk of proteinuria in the 9 trials (1214 women) reporting this outcome (RR 1.00; 95% CI 0.67 to 1.49) (Fig. 2b). Drug changes due to maternal side effects were reported in 4 small trials (360 women). Although the maternal side effects tended to be more apparent in women treated with antihypertensive drugs, there was no statistically significant difference (RR 2.69; 95% CI 0.32 to 22.64) (Fig. 2c). There was also no overall difference in the 8 trials (1239 women) reporting cesarean section (RR 0.97; 95% CI 0.82 to 1.15) (Fig. 2d).
Perinatal outcomes
Of the perinatal outcomes, neonatal and birth death was reported in 12 trials (1548 women) (RR 0.80; 95% CI 0.43 to 1.49) (Fig. 3a), preterm birth in 5 trials (904 women) (RR 0.86; 95% CI 0.53 to 1.39) (Fig. 3b), and small for gestational age infants in 9 trials (1082 women) (RR 1.04; 95% CI 0.66 to 1.63) (Fig. 3c). There is no clear evidence of an overall difference in the risk of these outcomes.
Risk of bias in the included studies
Risk of bias of the 14 trials was assessed in 7 areas. Methods for generating the random sequence were described 8 trials [7, 9, 10, 15,16,17,18, 20]. Inadequate methods were used in 2 trials [9, 18]. There were high risks of performance bias (blinding of participants and personnel) in 7 trials due to the open label nature of the study [9, 12, 15,16,17,18,19]. Two trials reported losses of greater than 10% of randomized women and were assessed as “high risk” for attrition bias [13, 16]. The shapes of the funnel plots in all outcomes did not reveal any evidence of obvious asymmetry. A representative funnel plot shows the symmetric distribution of the studies that evaluated the RR of the neonatal and birth death when comparing antihypertensive drugs or none (Fig. 4). Details of risk of bias are presented in Fig. 5. Although there was moderate to high inconsistency among trials in all outcomes, except for neonatal and birth death, there was no substantial variation in the effect estimates across studies, and there was a clear overlap of CIs among trials.
Discussion
In this review, we pooled studies that examined the effects of antihypertensive drugs on non-severe hypertension during pregnancy. There was no evidence to suggest that antihypertensive drug therapy reduced or increased the risk of maternal death, proteinuria, side effects, cesarean section, neonatal and birth death, preterm birth, or small for gestational age infants. Although antihypertensive drug therapy resulted in reduced risk for developing severe hypertension, there were no differences in the risk for eclampsia, stroke, or HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome when antihypertensive drug therapy was compared with the control (data not shown). In all outcomes, except for cesarean section, very small numbers of outcome events resulted in imprecise estimates. The quality of evidence was low, which was attributed to serious inconsistency and imprecision.
It is widely accepted that women with severe hypertension during pregnancy are at increased risk of fatal intracranial hemorrhage and require urgent and effective antihypertensive drug therapy [21, 22]. However, excessive BP lowering may impair placental vascularization and fetal development. Therefore, the benefits of antihypertensive drug therapy for women with HDP are to be weighed against the potential risk of fetal distress in the event of excessive BP lowering. Consistent with our results, a previous systematic review and meta-analysis revealed that there was not enough evidence to show the benefit of antihypertensive drugs for mild to moderate hypertension during pregnancy [23]. Moreover, the CHIPS trial, which randomized women with non-severe pregnancy hypertension to a diastolic BP target of 100 mmHg (“less tight” control) versus 85 mmHg (“tight” control), showed no significant between-group differences in the risk of pregnancy loss, high-level neonatal care, or overall maternal complications [24].
Limitations
This review has some limitations. First, the trials included in the study showed a relatively low level of quality because half of them failed to conduct a double-blind technique. Because almost all outcome data are only available from a small number of studies, reporting bias also needs to be taken into consideration. Second, no trials included in this review had a long-term follow-up. Women with HDP have been reported to be at high risk of later cardiovascular diseases, chronic kidney disease, and diabetes mellitus [25, 26]. However, the effects of antihypertensive drug therapy on the future cardiovascular and renal risk for mothers, as well as long-term child health, including attention deficit hyperactivity disorder, allergic diseases, and cardiovascular diseases after non-severe hypertension during pregnancy, are unknown. Third, the risks for maternal and/or perinatal outcomes of chronic hypertension might be different from those of gestational hypertension. However, because many trials included women with hypertensive disorders of pregnancy regardless of type of hypertension at trial entry, we could not evaluate the outcomes separately.
Conclusion
The current review suggests that antihypertensive drug therapy does not reduce or increase the risk of maternal death, proteinuria, side effects, cesarean section, neonatal and birth death, preterm birth, or small for gestational age infants. The quality of evidence was low. Therefore, it remains undetermined whether antihypertensive drug therapy for non-severe hypertension during pregnancy is worthwhile. Further studies are needed to build reliable estimates of the effectiveness and safety of antihypertensive drug therapy for women with HDP.
References
Cirillo PM, Cohn BA. Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. Circulation. 2015;132:1234–42.
Yoder SR, Thornburg LL, Bisognano JD. Hypertension in pregnancy and women of childbearing age. Am J Med. 2009;122:890–5.
American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–31.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Cochrane Statistical Methods G. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
Wide-Swensson DH, Ingemarsson I, Lunell NO, Forman A, Skajaa K, Lindberg B, et al. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. Am J Obstet Gynecol. 1995;173:872–8.
Pickles CJ, Broughton Pipkin F, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol. 1992;99:964–8.
Blake S, MacDonald D. The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment. Br J Obstet Gynaecol. 1991;98:244–8.
Pickles CJ, Symonds EM, Broughton Pipkin F. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989;96:38–43.
Rubin PC, Butters L, Clark DM, Reynolds B, Sumner DJ, Steedman D, et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet. 1983;1:431–4.
Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet. 1976;2:753–6.
Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301:587–9.
Weitz C, Khouzami V, Maxwell K, Johnson JW. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet. 1987;25:35–40.
Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992;167:879–84.
Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990;162:960–6. discussion966-967
Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol. 1987;70:323–7.
Molvi SN, Mir S, Rana VS, Jabeen F, Malik AR. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet. 2012;285:1553–62.
Elhassan EM, Mirghani OA, Habour AB, Adam I. Methyldopa versus no drug treatment in the management of mild pre-eclampsia. East Afr Med J. 2002;79:172–5.
Plouin PF, Breart G, Llado J, Dalle M, Keller ME, Goujon H, et al. A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynaecol. 1990;97:134–41.
Martin JN Jr., Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105:246–54.
Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011;118(Suppl 1):1–203.
Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;2:CD002252.
Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:407–17.
Mannisto T, Mendola P, Vaarasmaki M, Jarvelin MR, Hartikainen AL, Pouta A, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127:681–90.
Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10:e003497.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Ogura, S., Suzuki, J. & Suzuki, H. Antihypertensive drug therapy for women with non-severe hypertensive disorders of pregnancy: a systematic review and meta-analysis. Hypertens Res 42, 699–707 (2019). https://doi.org/10.1038/s41440-018-0188-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-018-0188-0
- Springer Nature Singapore Pte Ltd.